Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario, Canada

Archives of Internal Medicine

Volumn 163, Issue 4, 2003, Pages 467-472

  Muller, Matthew P ^a   Low, Donald E ^b   Green, Karen A ^b   Simor, Andrew E ^c   Loeb, Mark ^d   Gregson, Daniel ^e   McGeer, Allison ^b   Davies, H Dele ^f   John, Michael ^g   Saginur, Raphael ^h   Jessamine, Peter ^h   Talbot, James ⁱ   Lovgren, Marguerite ⁱ   Mederski, Barbara ^j   Sarabia, Alicia ^k   Trpeski, Liljana ^b   Willey, Barbara ^b   Plevneshi, Agron ^b   McArthur, Margaret ^b   Walmsley, Sharon ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e CALGARY LABORATORY SERVICES   (Canada)

^f ALBERTA CHILDREN'S HOSPITAL   (Canada)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ National Centre for Streptococcus   (Canada)

^j NORTH YORK GENERAL HOSPITAL   (Canada)

^k Peel Memorial Hospital   (Canada)

^l UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEPHALOSPORIN; IMMUNOGLOBULIN; MACROLIDE; PENICILLIN DERIVATIVE;

ADOLESCENT; ADULT; AGE; ANTIMICROBIAL THERAPY; ARTICLE; CANADA; CHILD; CLINICAL FEATURE; COMMUNICABLE DISEASE; FATALITY; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NECROTIZING FASCIITIS; NEWBORN; NURSING HOME; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIA; TOXIC SHOCK SYNDROME;

CHI-SQUARE DISTRIBUTION; CROSS INFECTION; DISEASE OUTBREAKS; FASCIITIS, NECROTIZING; HOSPITAL MORTALITY; HUMANS; INCIDENCE; ONTARIO; PNEUMONIA; POPULATION SURVEILLANCE; RISK FACTORS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 0037463565     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.4.467     Document Type: Article

References (53)

1. Keefer CS, Rantz LA, Rammelkamp OH. Hemolytic streptococcal pneumonia and empyema: a study of 55 cases with special reference to treatment. Ann Intern Med. 1941;14:1533-1550.
2. Parker MT. Necropsy studies of the bacterial complications of influenza. J Infect. 1979;1(suppl 2):9-16.
3. MacCallum WG. The Pathology of the Pneumonia in the United States Army Camps During the Winter of 1917-1918. New York, NY: Rockefeller Institute for Medical Research; 1919. Monograph 10.0
4. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, for the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31:383-421.
5. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ, for the Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
6. Levy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations. Chest. 1988;92:43-48.
7. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987;1:671-674.
8. Fang G, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore). 1990;69:307-316.
9. Lim I, Shaw DR, Stanley DP, Lumb R, McLennan G. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust. 1989;151:87-91.
10. Porath A, Schlaeffer F, Lieberman D. The epidemiology of community acquired pneumonias among hospitalized adults. J Infect. 1997;34:41-48.
11. Bohte R, vanFurth R, van den Brock PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax. 1995;50:543-547.
12. Lieberman D, Schlaeffer F, Bolden I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 1996;51:179-184.
13. Bates JH, Campbell GD, Barron AL, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest. 1992;101:1005-1012.
14. Gerber GJ, Farmer WC, Fulkerson LL. β-Hemolytic streptococcal pneumonia following influenza. JAMA. 1978;240:242-243.
15. Birch C, Gowardman J. Streptococcus pyogenes: a forgotten cause of severe community-acquired pneumonia. Anaesth Intensive Care. 2000;28:87-90.
16. Kalima P, Riordan T. Necrotizing pneumonia associated with group A streptococcal bacteremia. Eur J Clin Microbiol Infect Dis. 1998;17:296-298.
17. Clementsen P, Milman N. Bilateral pulmonary abscesses caused by Streptococcus pyogenes: diagnostic importance of fiberoptic bronchoscopy. Scand J Infect Dis. 1994;26:755-757.
18. Hamour A, Bonnington A, Wilkins EG. Severe community acquired pneumonia associated with a desquamating rash due to group A β-hemolytic streptococcus. J Infect. 1994;29:77-81.
19. Frieden TR, Biebuyck J, Hierholzer WJ. Lung abscess with group A β-hemolytic streptococcus: case report and review. Arch Intern Med. 1991;151:1655-1657.
20. McIntyre HD, Armstrong JG, Mitchel CA. Streptococcus pyogenes pneumonia with abscess formation. Aust N Z J Med. 1989;19:248-249.
21. McMurray JJ, Fraser DM, Brogan O. Fatal Streptococcus pyogenes pneumonia. J R Soc Med. 1987;80:525-526.
22. Barnham M, Weightman N, Anderson A, Pagan F, Chapman S. Review of 17 cases of pneumonia caused by Streptococcus pyogenes. Eur J Clin Microbiol Infect Dis. 1990;18:506-509.
23. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med. 1996;335:547-554.
24. Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis. 1993;16:792-800.
25. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet. 1990;336:1167-1171.
26. Martin PR, Hoiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis. 1990;22:421-429.
27. Gaworzewska E, Colman G. Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol Infect. 1988;100:257-269.
28. Givner LB, Abramson JS, Wasilauskas B. Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. J Pediatr. 1991; 118:341-346.
29. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987;317:146-149.
30. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321:1-7.
31. Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definitions. JAMA. 1993; 269:390-391.
32. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988 [published correction appears in Am J Infect Control. 1988;16:177]. Am J Infect Control. 1988;16:128-140.
33. Griffith F. Serological classification of Streptococcus pyogenes. J Hyg. 1934;34:542-584.
34. Maxted WR, Widdowson JP, Fraser CA, Ball LC, Bassett DC. The use of the serum opacity reaction in the typing of group-A streptococci. J Med Microbiol. 1973;6:83-90.
35. Rotta J, Krause RM, Lancefield RC, Everly W, Lackland H. New approaches for the laboratory recognition of M types of group A streptococci. J Exp Med. 1971;134:1298-1315.
36. Single LA, Martin DR. Clonal differences within M-types of the group A streptococcus revealed by pulsed field gel electrophoresis. FEMS Microbiol Lett. 1992;70:85-89.
37. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: a retrospective population-based study [published correction appears in JAMA. 1993;269:1638]. JAMA. 1993; 269:384-389.
38. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network. Group A Streptococcus, 1997-99. Available at: http://www.cdc.gov/ncidod/dbmd/abcs. Accessed January 2001.
39. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med. 1997;157:1709-1718.
40. Basiliere JL, Bistrong HW, Spence WF. Streptococcal pneumonia: recent outbreaks in military recruit populations. Am J Med. 1969;44:580-589.
41. Welch CC, Tombridge TL, Baker WJ, Kinney RJ. Beta-hemolytic streptococcal pneumonia: report of an outbreak in a military population. Am J Med Sci. 1961; 242:157-165.
42. Schwartz B, Elliott JA, Butler JC, et al. Clusters of invasive group A streptococcal infections in family, hospital and nursing home settings. Clin Infect Dis. 1992; 15:277-284.
43. Gamba MA, Martinelli M-A, Schaad HJ, et al. Familial transmission of a serious disease-producing group A streptococcus clone: case reports and review. Clin Infect Dis. 1997;24:1118-1121.
44. A household cluster of fulminant group A streptococcal pneumonia associated with toxic shock syndrome - Quebec, Canada. Commun Dis Rep. 1996;22(6):41-43.
45. Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive group A streptococcal disease among household contacts of case-patients: is prophylaxis warranted? JAMA. 1998;279:1206-1210.
46. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med. 1999; 107(suppl 1A):34S-43S.
47. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223-229.
48. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30:520-528.
49. Morris AM, Davis R, Dedier J, et al. Survival of bacteremic pneumococcal pneumonia in Toronto, Ontario 1995-1998. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-19, 2000; Toronto, Ontario. Abstract 1859.
50. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 1999;28:800-807.
51. Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun. 1996;64:3595-3598.
52. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol. 1996;156:3057-3064.
53. Perez CM, Kubak BM, Cryer HG, Salehmugodam S, Vespa P, Farmer D. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Am J Med. 1997;102:111-113.